Last week, a Judge of the US Federal Court for the Central District of California issued an interesting order holding that a generic manufacturer of the antidepressant Prozac could have warned about an increased risk of suicide associated with its prescription medication by changing its labels without approval from the U.S. Food and Drug Administration. The order,
Dorsett v Sandoz is available
here. The decision echoes similar rulings in the 5th, 4th and 8th circuits, but the it creates a split among district courts in the 9th Circuit. For more on this story go
here.
No comments:
Post a Comment